Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

<p>Multiplex immunohistochemical staining protocols.</p>

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Hansol Lee (15054787) (author)
Diğer Yazarlar:	Angela L. Ferguson (15050051) (author), Camelia Quek (15049218) (author), Ismael A. Vergara (15054784) (author), Ines Pires daSilva (15056800) (author), Ruth Allen (15056803) (author), Tuba Nur Gide (15056806) (author), Jordan W. Conway (15056809) (author), Lambros T. Koufariotis (15056812) (author), Nicholas K. Hayward (14956488) (author), Nicola Waddell (12694196) (author), Matteo S. Carlino (15056815) (author), Alexander M. Menzies (11420816) (author), Robyn P.M. Saw (15056818) (author), Elena Shklovskaya (15056821) (author), Helen Rizos (15008946) (author), Serigne Lo (15056824) (author), Richard A. Scolyer (10778711) (author), Georgina V. Long (11420813) (author), Umaimainthan Palendira (15050084) (author), James S. Wilmott (15008931) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Cancer Detection and Diagnosis Immuno-oncology Biomarkers Prognostic biomarkers Immunology Immune responses to cancer Innate immunity Tumor-associated macrophages Immunotherapy Biomarkers for immunotherapy Checkpoint blockade Combination immunotherapy Skin Cancers Melanoma
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Yazar:: Hansol Lee (15054787)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Yazar:: Hansol Lee (15054787)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Yazar:: Hansol Lee (15054787)
Baskı/Yayın Bilgisi: (2025)

Supplementary Tables from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages
Yazar:: Renumathy Dhanasekaran (14962092)
Baskı/Yayın Bilgisi: (2025)

Table S2, S4, S5, S6 and S7 from Single-Cell Analysis Reveals a CD4<sup>+</sup> T-cell Cluster That Correlates with PD-1 Blockade Efficacy
Yazar:: Hiroshi Kagamu (14961732)
Baskı/Yayın Bilgisi: (2025)

Supplementary File 1 from Cetuximab Responses in Patients with HNSCC Correlate to Clonal Expansion Feature of Peripheral and Tumor-Infiltrating T Cells with Top T-Cell Receptor Clonotypes
Yazar:: Huaibin Ge (15047462)
Baskı/Yayın Bilgisi: (2025)

Suppl video 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Yazar:: Andrew O. Yam (15293045)
Baskı/Yayın Bilgisi: (2025)

Suppl video 2 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Yazar:: Andrew O. Yam (15293045)
Baskı/Yayın Bilgisi: (2025)

Suppl video 3 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Yazar:: Andrew O. Yam (15293045)
Baskı/Yayın Bilgisi: (2025)

Suppl video 4 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Yazar:: Andrew O. Yam (15293045)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Yazar:: Andrew O. Yam (15293045)
Baskı/Yayın Bilgisi: (2025)

Supplementary figures and tables FTS1 from Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial
Yazar:: Daniel S. Green (15047598)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
Yazar:: Carlotta Antoniotti (15352506)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
Yazar:: Carlotta Antoniotti (15352506)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S3 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
Yazar:: Carlotta Antoniotti (15352506)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 1 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
Yazar:: Caroline Robert (15032672)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 2 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
Yazar:: Caroline Robert (15032672)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 3 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
Yazar:: Caroline Robert (15032672)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 4 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
Yazar:: Caroline Robert (15032672)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 1 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
Yazar:: Arianna Draghi (15126339)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 2 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
Yazar:: Arianna Draghi (15126339)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 3 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
Yazar:: Arianna Draghi (15126339)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Yazar:: Jonathan M.J. Derry (16648337)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Yazar:: Jonathan M.J. Derry (16648337)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Yazar:: Jonathan M.J. Derry (16648337)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S4 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Yazar:: Jonathan M.J. Derry (16648337)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S5 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Yazar:: Jonathan M.J. Derry (16648337)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S6A from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Yazar:: Jonathan M.J. Derry (16648337)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S6B from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Yazar:: Jonathan M.J. Derry (16648337)
Baskı/Yayın Bilgisi: (2025)

Figure S1 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Yazar:: Jian Wang (15048011)
Baskı/Yayın Bilgisi: (2025)

Figure S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Yazar:: Jian Wang (15048011)
Baskı/Yayın Bilgisi: (2025)

Figure S3 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Yazar:: Jian Wang (15048011)
Baskı/Yayın Bilgisi: (2025)

Figure S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Yazar:: Jian Wang (15048011)
Baskı/Yayın Bilgisi: (2025)

Figure S5 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Yazar:: Jian Wang (15048011)
Baskı/Yayın Bilgisi: (2025)

Figure S6 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Yazar:: Jian Wang (15048011)
Baskı/Yayın Bilgisi: (2025)

Figure S7 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Yazar:: Jian Wang (15048011)
Baskı/Yayın Bilgisi: (2025)

Figure S8 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Yazar:: Jian Wang (15048011)
Baskı/Yayın Bilgisi: (2025)

Table S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Yazar:: Jian Wang (15048011)
Baskı/Yayın Bilgisi: (2025)

Table S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Yazar:: Jian Wang (15048011)
Baskı/Yayın Bilgisi: (2025)

Supplementary Fig. S1 from The mTOR Signaling Pathway Interacts with the ER Stress Response and the Unfolded Protein Response in Cancer
Yazar:: Sahar Mafi (16721657)
Baskı/Yayın Bilgisi: (2025)

Cannot write session to /tmp/vufind_sessions/sess_fb5rfrtggmruafoj62kjbd24fo